Bruno Flamion is a Belgian national, MD/PhD from the University of Brussles, specialist in internal medicine and nephrology and full Professor of physiology and pharmacology at the University of Namur, Belgium (since 1998). He has been a medical and pharmacological expert for the Belgian Federal Agency for Medicines and Health Products (FAMHP) for 12 years and has worked for the European Medicines Agency (EMA) in London for 10 years, acting as CHMP member, vice-chair of the Pharmacogenomics Working Party, chair of the Pharmacokinetics group, and chair of the Scientific Advice Working Party for 6 years (2005 - 2010).
Bruno Flamion has also chaired the Committee for Reimbursement of Medicines in Belgium (2010 - 2012). This Committee is part of the National Insitute for Health and Disability Insurance. Bruno is a member of Regulatory Advisory Boards of CIRS (Center for Innovation in Regulatory Science) and NDA. Bruno's interests lie in clinical pharmacology, drug development (both regulatory and health technology assessment/reimbursement aspects), patient care and basic research.